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Objectives: To develop an operational definition of contextual factors (CF) [1].
Methods: Based on previously conducted interviews, we presented three CF types in a Delphi survey; Effect
Modifying -, Outcome Influencing - and Measurement Affecting CFs. Subsequently, a virtual Special Interest
Group (SIG) session was held for in depth discussion of Effect Modifying CFs.
Results: Of 161 Delphi participants, 129 (80%) completed both rounds. After two rounds, we reached consen-
sus (70% agreeing) for all but two statements. The 45 SIG participants were broadly supportive.
Conclusion: Through consensus we developed an operational definition of CFs, which was well received by
OMERACT members.




Effect modifying contextual factors
Outcome explaining contextual factors
Measurement affecting contextual factorsIntroduction
The Outcome Measures in Rheumatology (OMERACT) initiative [1]
established the Contextual Factors Working Group to guide the
understanding, identification and handling of contextual factors (CFs)
in clinical trials [2,3] (https://omeract.org/working-groups/contex
tual-factors/). Initially, OMERACT defined a CF as a “variable that is
not an outcome of the study, but needs to be recognized (and measured)
to understand the study results. This includes potential confounders and
effect modifiers” [4].
The working group explored patient, clinician and researcher per-
spectives in semi-structured interviews [5] and identified four types
of CFs describing different ways that CFs can influence trial results.
These CF types were initially termed Effect Modifying (EM-CFs), Meta
Confounding (MC-CFs), Measurement Affecting (MA-CFs) and Out-
come Explaining (OE-CFs). Of these, three are relevant for individual
clinical trials (i.e. EM-CFs, MA-CFs, OE-CFs) and, hence, OMERACT [5].
In this study, we aimed to develop a consensus-based operational
definition of CFs, that is a definition that can be used to guide the
understanding, identification and handling of CFs in individual clini-
cal trials within rheumatology.Methods
This study represents the two final stages of a mixed methods
study consisting of i) semi-structured interviews [5], ii) an iterative
consensus Delphi survey and iii) a virtual Special Interest Group (SIG)
session for discussion.
For the Delphi, we followed a predefined protocol, based on rele-
vant guidelines [68]. The study was carried out in accordance with
the Helsinki Declaration and approved by the Danish Data Protection
Agency (ID 06,081, BFH-2017127).
We developed the Delphi survey based on findings from our semi-
structured interviews [5]. We invited all 974 listed members of the
OMERACT community (including 85 patient research partners) to par-
ticipate in the online Delphi survey. The survey included a section for
each of the three CF types (EM-CFs, OI-CFs and EM-CFs) and an over-
arching section addressing general issues. Each section was introduced
with a description including a case scenario, followed by statements to
be rated on a Likert numeric rating scale from 1 to 9 (13, Disagree;
46, Undecided; 79, Agree), with the option ‘Unable to score’ and to
provide comments. Agreement by stakeholders (i.e. patients and clini-
cians/others) required 70% scoring 7 to 9 and disagreement required
70% scoring 1 to 3 [6]. Consensus was achieved if both stakeholder
groups agreed (or disagreed) with the statement.
We conducted two survey rounds in 2020, from March 2nd to
April 6th and June 15th to July 23rd respectively. Everyone who
signed up as participant were invited for both rounds, whether or not
they completed the first round. Between rounds, the steering group
discussed the results and feedback and agreed on modifications of
the descriptions and statements. The participants were informed
about modifications and their previous ratings (if any) beforeinitiating the next round. We used DelphiManager software (www.
comet-initiative.org/delphimanager/), that ensures confidentiality.
Participants could offer consent if they agreed to being contacted
regarding comments needing further clarifications. We analysed data
using R (version 4.0.1) [9]. See protocol and protocol deviations for
further details on methods (supplemental material).
We conducted a 1-hour virtual SIG session on November 12th as
part of the virtual OMERACT 2020 meeting, for which the OMERACT
secretary invited all OMERACTmembers and others interested via email
and social media (Facebook, Twitter and LinkedIn). We developed pre-
paratory material based on the Delphi results, including two videos, a
quiz, a lay summary, a glossary list and a pre-reading text. Further, we
asked participants to provide published examples of EM-CFs in advance.
The session focussed on EM-CFs due to previous progress and limited
time. During the session, we presented EM-CFs in further detail, allow-
ing for further discussion and understanding of the concept of EM-CFs.Results
A total of 161 individuals signed up for our Delphi survey (Fig. 1),
including 33 (20%) patients and 128 (80%) clinicians/others. Of these,
29 (88%) patients and 100 (78%) clinicians/others completed both
survey rounds fully.
The patients signing up for the Delphi were 24 (73%) females,
mean age was 57.1 (SD, 11.1) and represented a wide range of rheu-
matic conditions, but mostly rheumatoid arthritis (30%), psoriatic
arthritis (21%) and osteoarthritis (12%). Clinicians/others signing up
were 71 (55%) females, mean age was 51.3 (SD, 11.9) and 80 (63%)
were involved in rheumatology patient care. Forty-three (out of 44
active) OMERACT working groups and 26 countries from five conti-
nents, but mostly North America and Europe, were represented (see
all characteristics in supplemental material).
In round 1, consensus was achieved for 19 out of 28 statements
(68%). The participants provided 394 comments on the statements, 38
general comments and 11 suggestions for additional statements. State-
ments with no consensus were mainly related to OE-CFs and many
participants expressed difficulty distinguishing between the CF types.
This guided the modifications for round 2. ‘Outcome Explaining’ CFs
were now called ‘Outcome Influencing’ CFs (OI-CFs) and the descrip-
tion was rewritten. For round 2, 14 statements with consensus were
removed, some were reformulated and 6 new statements were added.
In round 2, consensus was achieved for 18 out of 20 statements
(90%), with 36 general comments. Lack of consensus was related to
classification categories for the MA-CFs (see details in supplemental
material). The steering group deemed the two statements less impor-
tant and conducting a third survey round was not necessary. Two
important overarching statements, which reached consensus, were ‘I
consider the three types of contextual factors to adequately cover the
concept contextual factors’ (97% and 92% patients and clinicians/others
agreeing, respectively) and ‘I can distinguish between the three differ-
ent types of contextual factors’ (93% and 86% agreeing) (see survey
results in supplemental material).
Fig. 1. Flow diagram for the Delphi survey (A) and the virtual Special Interest Group session (B). *The OMERACT member mail list include 974 email addresses, of which 85 are
patients. However, it is anticipated that the list includes many that are no longer active OMERACT members, have retired, or for other reasons are not possible to reach through e-
mail contact. y129 completed the full surveys in both rounds. z The OMERACT secretary invited potentially interested people outside OMERACT to join the virtual sessions as part of
the OMERACT 2020 virtual meeting via social media (i.e. Facebook, Twitter and LinkedIn). OMERACT, Outcome Measures in Rheumatology; SIG, Special Interest Group.
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nition of CFs (Fig. 2) and presented it as part of the preparatory mate-
rial for the SIG session (see supplemental material).
Forty-five individuals attended our virtual SIG (Fig. 1); 14 (31%)
patients, 30 (67%) clinicians/researchers and 1 (2%) regulator, repre-
senting 17 countries from 4 continents. Thirty-four (76%) hadFig. 2. Overview of the consensus-based operational definition of contextual factors. The thr
the results of a trial. Brief descriptions of each type are shown on the figure. All three are des
considered within each of these types, specific factors must fit within one of the three class
contextual factor types are not mutually exclusive, so some specific factors may both be an
patient subgroups experience greater or less effect from a treatment compared to other subg
ing the course of a patient’s condition and may confound the results of trials which are not r
(such as reliability, validity, responsiveness, etc.). CFs, Contextual Factors.participated in our Delphi survey. Of our preparatory material,
the two videos were the most popular, and only 2 (5%) had not
used any material (Fig. 3). In advance, 8 SIG participants (2 patients
and 6 clinicians/researchers) had provided examples of EM-CFs
for the session. Three examples were selected and presented
[1012].ee contextual factor types describe different ways that contextual factors can influence
cribed in detail in the supplementary material. To guide which possible factors could be
ification categories, i.e. either personal-, disease-related, or environmental factors. The
EM-CFs, OI-CFs and MA-CF. In short, EM-CFs modifies the treatment effect (i.e. some
roups). OI-CFs are prognostic factors (sometimes called risk factors), i.e. factors predict-
andomized. MA-CFs influences the performance of outcome measurement instruments
Fig. 3. Poll results from virtual Special Interest Group (SIG) session. Distribution of participants according to stakeholder groups and country of residence. Two polls were used dur-
ing the session. Black indicate clinicians/researchers/others and white indicate patients. The first poll asked participants which preparatory material they had used (left) and it was
possible to pick several options. The second poll included two questions (right), asking the participants about their understanding of EM-CFs and whether they considered the key
criteria for EM-CFs useful, respectively, and it was only possible to pick one option for each question. EM-CFs, Effect Modifying Contextual Factors; RCT, Randomized Controlled
Trial.
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discussions, and statistical questions were frequent. It was empha-
sized that trial reports should present treatment effects separately
for subgroups according to EM-CFs (e.g. in their appendix), to make
these available for future meta-analyses. P-values for interaction tests
are generally being phased out due to risk of type-II errors.
Distinguishing EM-CFs from OI-CFs was mentioned as a challenge,
but one suggested that OI-CFs relates to the disease progression,
while EM-CFs relates to the treatment effect. Some were concerned
that EM-CFs may depend on the intervention, but it was clarified that
we will initially look for factors frequently shown and/or strongly
suspected to be EM-CFs across different interventions. The OMERACT
working groups should not be responsible for providing such evi-
dence, when identifying EM-CF for their core sets, but simply note
where more research is needed.
The poll indicated that most SIG participants understood the con-
cept of EM-CFs ‘very well’ and found the criteria ‘very helpful’ (Fig. 3).
After the session, the recording was made available online (available
from the corresponding author).
Discussion
In this study, we achieved consensus on an operational definition
of CFs including three types (i.e. EM-CFs, MA-CFs and OI-CFs) and
introduced it to the OMERACT community. We believe this definition
will help to resolve most of the confusion related to CFs, as our elabo-
ration of the initial OMERACT definition embraces different views on
CFs.Our work is likely relevant across most OMERACT working groups.
EM-CFs are relevant for all groups developing core outcome sets for
clinical trials. OI-CFs relates to non-randomized trials and may be rel-
evant for groups such as the Patient Outcomes in Longitudinal Obser-
vational Studies (POLOS) group (website: https://omeract.org/
working-groups/polos/) and work productivity [13]. MA-CFs are rele-
vant for all groups developing core outcome measurement sets [14].
Some groups work with concepts related to MA-CFs, such as the
equity extension for the OMERACT instrument selection process
(website: https://omeract.org/working-groups/health-equity/) and
sources of variability for outcome measurement instruments by the
Imaging group [15].
Consideration of CFs has the potential to improve the measure-
ment of outcomes (i.e. MA-CFs), to improve the interpretation of
non-randomized trials and identification of patients with poor prog-
nosis (i.e. OI-CFs), and to improve the treatment of patients (i.e. EM-
CFs). Strengths of our work include the large number and interna-
tional representation of the participants. Active engagement led to
many comments from different perspectives, which guided the modi-
fications of our definition. However, the material was only provided
in English, and individuals from Africa, Asia and South America were
under-represented. We consider our definition to be provisional,
allowing for future adjustments if necessary.
In conclusion, we have developed and achieved OMERACT agree-
ment on an operational definition of CFs. We anticipate this definition
will improve understanding, identification and handling of CFs when
developing core outcome sets within OMERACT, as well as facilitate
research on CFs generally within rheumatology.
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